Genetic basis of Hypertrophic Cardiomyopathy in Sphynx cats - is linked to a genetic mutation in the ALMS1 gene. This mutation involves a G/C variant in exon 12 of ALMS1, which changes a highly conserved glycine amino acid to an arginine, altering the protein structure and function. The mutation has incomplete penetrance, meaning not all cats carrying the mutation will develop the disease. About 60% of affected Sphynx cats carry this mutation. Both heterozygous (one copy) and homozygous (two copies) carriers exist, but currently, it is unclear if homozygous cats have a higher risk of disease. Some affected cats do not carry this mutation, indicating other unidentified mutations may also contribute to HCM in Sphynx cats.
Pathophysiology - The ALMS1 gene encodes a protein involved in cell cycle regulation and possibly cardiac development. The mutation disrupts normal heart muscle cell function, leading to myofiber disarray and interstitial fibrosis in the myocardium. This causes thickening of the heart muscle (hypertrophy), especially in the left ventricle, impairing cardiac function. The disease develops most commonly in adult cats around 2-3 years of age but can present later. The thickened heart muscle reduces chamber compliance, causing diastolic dysfunction and increasing the risk of heart failure and sudden cardiac death.
Complications - Cats affected by Sphynx-type HCM may experience: Progressive thickening of the left ventricular heart muscle. Diastolic dysfunction, leading to congestive heart failure. Arrhythmias and increased risk of sudden cardiac death. Variable age of onset, typically between 2-3 years but as late as 8-10 years. Some affected cats live into their teens without severe disease progression. Potential for incomplete penetrance means some carriers do not develop clinical signs.
Why This Matters to Breeders and Vets - Genetic Testing: DNA tests can identify cats with the ALMS1 mutation to aid breeders in avoiding mating two carriers, which could produce homozygous offspring at risk. Breeding Decisions: It is recommended not to breed two carriers together given the potential risk for affected offspring. Breeding a heterozygous carrier to a negative cat and screening kittens is advised. Veterinary Management: Knowing a cat’s genetic status helps vets monitor for early cardiac changes and manage the disease proactively. Incomplete Penetrance: Since not all cats with the mutation develop HCM, regular cardiac screening remains important even in genetically positive cats. Further Research Needed: The presence of disease in cats without the known ALMS1 mutation suggests additional genetic factors to be discovered, emphasizing the need for ongoing genetic research in Sphynx HCM.
Summary - Hypertrophic Cardiomyopathy in Sphynx cats is primarily associated with a novel mutation in the ALMS1 gene that disrupts normal cardiac muscle cell function leading to heart muscle thickening and potential heart failure. The mutation shows incomplete penetrance, affecting about 60% of cases. Genetic testing helps breeders reduce disease incidence by informed mating strategies and assists veterinarians in early diagnosis and management. Ongoing research continues to clarify the genetic complexity of HCM in Sphynx cats, highlighting the importance of comprehensive screening and awareness in the breed.